Global Cataracts Market
Market Size in USD Billion
CAGR :
% 
USD
5.59 Billion
USD
8.92 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 5.59 Billion |
 Market Size (Forecast Year) |
USD 8.92 Billion |
 CAGR |
% |
| Major Markets Players |
|
Global Cataracts Market Segmentation, By Type (Nuclear Cataract, Cortical Cataract, Posterior Subcapsular Cataract, Congenital Cataracts, and Others), Diagnosis (Visual Acuity Test, Slit-Lamp Examination, Retinal Exam, and Others), Treatment (Surgery), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) - Industry Trends and Forecast to 2032
Cataracts Market Size
- The global cataracts market size was valued at USD 5.59 billion in 2024 and is expected to reach USD 8.92 billion by 2032, at a CAGR of 6.0% during the forecast period
- The increasing prevalence of cataracts among the elderly is a major driver, especially in countries with expanding geriatric demographics such as Japan, Germany, and the U.S.
- Furthermore, the innovations such as femtosecond laser-assisted cataract surgery (FLACS) and premium intraocular lenses (IOLs) are transforming patient outcomes and driving demand
Cataracts Market Analysis
- Cataract surgeries are becoming increasingly essential in modern ophthalmic care due to their proven ability to restore vision, enhance quality of life, and reduce the risk of falls and related complications, especially in the elderly
- The surging demand for cataract treatment is driven by a combination of factors including the rising incidence of age-related eye disorders, technological advancements in intraocular lenses (IOLs), and improved access to surgical care across both developed and developing regions
- North America dominated the cataracts market with the largest revenue share of 39.15% in 2024, to the region’s advanced healthcare infrastructure, early adoption of cutting-edge cataract surgical technologies, and favorable reimbursement policies. The U.S., in particular, continues to witness high surgical volumes, fueled by increased awareness, a growing elderly population, and the availability of premium intraocular lenses (IOLs)
- Asia-Pacific is expected to be the fastest growing region with a CAGR of 9.2% in the cataracts market during the forecast period due to increasing urbanization, rising healthcare expenditure, expanding access to ophthalmic care, and government-supported initiatives to eliminate preventable blindness
- The surgery segment dominated the cataracts market with a market share of 38.5% in 2024, owing to its status as the primary and most effective treatment option for cataracts
Report Scope and Cataracts Market Segmentation
|
Attributes |
Cataracts Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
North America
Europe
Asia-Pacific
Middle East and Africa
South America
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, pricing analysis, brand share analysis, consumer survey, demography analysis, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Cataracts Market Trends
“Enhanced Outcomes Through AI, Robotics, and Personalized Care”
- A growing trend in the global cataracts market is the integration of artificial intelligence (AI) and robotics into cataract diagnostics, surgical planning, and post-operative care. These technologies are enhancing precision, efficiency, and patient-specific outcomes
- For instance, Alcon’s Vivity and PanOptix IOLs are part of a new wave of premium lenses that provide extended depth of focus, supported by AI-driven customization in lens selection based on patient lifestyle and vision requirements
- Robotic-assisted cataract surgeries, powered by platforms such as the Catalys Precision Laser System (Johnson & Johnson Vision) and LenSx (Alcon), are gaining traction in developed markets. These systems use real-time imaging and laser precision to improve surgical outcomes
- AI-powered diagnostic platforms, such as those offered by Topcon and Zeiss, can analyze retinal scans to detect early-stage cataracts and other ocular conditions, facilitating early diagnosis and intervention
- In addition, the trend toward outpatient and ambulatory surgical centers (ASCs), equipped with advanced imaging, femtosecond lasers, and AI integration, is revolutionizing how cataract surgeries are delivered—minimizing hospital stay times and reducing healthcare costs
- This move toward personalized cataract care, supported by real-time data, digital diagnostics, and robotic precision, is reshaping both patient expectations and ophthalmology standards globally
Cataracts Market Dynamics
Driver
“Rising Global Burden of Vision Impairment and Advancements in Cataract Surgery”
- The increasing global burden of vision impairment due to age-related cataracts is a major driver for the market. According to the World Health Organization (WHO), cataracts remain the leading cause of blindness globally, affecting over 65 million people
- With aging populations in regions such as North America, Europe, and Asia-Pacific, the demand for effective and rapid cataract treatment is rising. For instance, India's National Program for Control of Blindness (NPCB) is scaling up free cataract surgeries to reduce avoidable blindness
- Key companies such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb are launching next-gen IOLs that not only restore vision but also reduce dependence on glasses—driving the premium IOL segment forward
- The shift from traditional extracapsular surgery to phacoemulsification and femtosecond laser-assisted cataract surgery (FLACS) has enhanced surgical precision, minimized healing time, and reduced complications
- Moreover, the expansion of cataract surgery in emerging markets—via mobile eye units, public-private partnerships, and teleophthalmology—is unlocking major growth potential, particularly across Latin America and Sub-Saharan Africa
Restraint/Challenge
“High Cost of Advanced Cataract Procedures and Limited Access in Rural Areas”
- While cataract surgery is widely recognized as cost-effective, the high upfront cost of premium IOLs and advanced surgical equipment poses a barrier to adoption, particularly in low- and middle-income countries
- Access remains a major challenge in rural and underserved regions, where the lack of trained ophthalmologists and infrastructure results in treatment backlogs. For instance, despite India performing over 6 million cataract surgeries annually, rural areas still face long waiting times and accessibility issues
- Advanced procedures such as FLACS and toric/multifocal IOL implants are often not covered under standard public insurance or government schemes, limiting their reach to high-income patients or private care settings
- Leading companies such as Zeiss and Rayner are focusing on scaling down premium lens prices and expanding surgical platforms into Tier 2 and Tier 3 cities globally to address this imbalance
- Another challenge is the post-operative care and follow-up, which may not be accessible for elderly or low-income patients, impacting long-term outcomes despite successful surgeries
Cataracts Market Scope
The market is segmented on the basis of type, diagnosis, treatment, end user and distribution channel.
- By Type
On the basis of type, the cataracts market is segmented into nuclear cataract, cortical cataract, posterior subcapsular cataract, congenital cataracts, and others. The nuclear cataract segment dominated in 2024, accounting for 38.4% of the market, driven by its high prevalence in the aging population and the frequency of associated surgical interventions
The posterior subcapsular cataracts segment is anticipated to witness the fastest growth rate of 21.7% from 2025 to 2032, owing to its rapid progression and increasing diagnosis among diabetic and steroid-using patients.
- By Diagnosis
On the basis of diagnosis, the cataracts market is segmented into visual acuity test, slit-lamp examination, retinal exam, and others. The slit-lamp examination held the largest market revenue share in 2024 driven by the due to its critical role in detecting and assessing cataracts in early and advanced stages.
The retinal exam segment is expected to witness the fastest CAGR from 2025 to 2032, driven by supported by technological advancements in retinal imaging and its growing use in detecting coexisting ocular conditions that may influence surgical planning.
- By Treatment
On the basis of treatment, the cataracts market is segmented into surgery. The surgery segment held the largest market revenue share of 38.5% in 2024, as it remains the only effective and definitive treatment for cataracts. The widespread adoption of advanced surgical techniques such as phacoemulsification and femtosecond laser-assisted surgery continues to drive this segment's dominance and growth potential.
- By End-Users
On the basis of end-users, the cataracts market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment accounted for the largest market revenue share in 2024, driven by the availability of skilled ophthalmologists, advanced surgical infrastructure, and high patient inflow for cataract surgeries.
The specialty clinics segment is expected to witness the fastest CAGR from 2025 to 2032, driven by their focus on outpatient cataract procedures, shorter waiting times, and personalized care.
- By Distribution Channel
On the basis of distribution channel, the cataracts market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment accounted for the largest market revenue share in 2024, supported by direct procurement of post-surgical medications and follow-up treatments.
The hospital pharmacy segment is expected to witness the fastest CAGR from 2025 to 2032, driven by increasing digitalization in healthcare access and the growing demand for doorstep delivery of ophthalmic drugs.
Cataracts Market Regional Analysis
- North America dominated the cataracts market with the largest revenue share of 39.15% in 2024, driven by a high prevalence of age-related cataracts and widespread access to advanced surgical procedures such as phacoemulsification and femtosecond laser-assisted cataract surgery.
- Favorable reimbursement policies, growing awareness about ocular health, and the presence of key players offering innovative intraocular lenses (IOLs) continue to support strong market growth.
- In addition, the rising geriatric population and high healthcare expenditure in the region are accelerating the demand for timely diagnosis and surgical treatment of cataracts
U.S. Cataracts Market Insight
The U.S. cataracts market captured the largest revenue share of 80.5% in 2024 within North America, due to the increasing burden of cataract cases among the aging population and the rapid adoption of premium IOLs. Continued advancements in minimally invasive surgical technologies and strong presence of ophthalmic centers specializing in cataract care are major growth drivers. Moreover, the rising demand for outpatient cataract surgeries and growing acceptance of elective lens replacement procedures is further contributing to market expansion.
Europe Cataracts Market Insight
The Europe cataracts market is projected to expand at a substantial CAGR throughout the forecast period, supported by increasing demand for improved visual outcomes and growing government initiatives for cataract screening programs. Aging demographics, particularly in countries such as Germany, France, and Italy, and the availability of public health systems providing subsidized surgical treatment are enhancing market penetration. In addition, a shift towards premium lens implants is gaining momentum in private healthcare settings.
U.K. Cataracts Market Insight
The U.K. cataracts market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increased NHS funding for cataract surgeries and growing awareness of early diagnosis. The expansion of private ophthalmology clinics, adoption of laser-assisted cataract surgeries, and rising demand for monofocal and multifocal IOLs are also boosting growth. The market benefits from efforts to reduce surgical wait times through mobile surgical units and community-based diagnostic pathways.
Germany Cataracts Market Insight
The Germany cataracts market is expected to expand at a considerable CAGR during the forecast period, fueled by a strong healthcare infrastructure and early adoption of advanced technologies in eye care. High awareness about cataract symptoms and the availability of skilled ophthalmic surgeons have increased the uptake of surgical treatments. Moreover, increased use of toric and presbyopia-correcting lenses is improving patient satisfaction and reinforcing market trends in both public and private settings.
Asia-Pacific Cataracts Market Insight
The Asia-Pacific cataracts market is poised to grow at the fastest CAGR of 9.2% during the forecast period of 2025 to 2032, driven by rapid population aging, expanding healthcare access, and government initiatives for blindness prevention. Countries such as India and China are scaling up cataract surgery outreach programs and public-private partnerships to reduce cataract-related visual impairment. The increasing affordability of surgical consumables and IOLs is also improving surgical volume across rural and urban areas.
Japan Cataracts Market Insight
The Japan cataracts market is gaining momentum due to the country’s large elderly population and high incidence of cataract-induced vision loss. The market benefits from early diagnosis, well-established reimbursement systems, and technological innovation in ophthalmic surgery. Demand is also rising for customizable IOLs, especially among patients seeking refractive correction. Increasing patient preference for day-care surgeries and enhanced recovery protocols is further supporting market growth.
China Cataracts Market Insight
The China cataracts market accounted for the largest market revenue share in Asia-Pacific in 2024, supported by strong government programs such as the National Cataract Elimination Project. Rapid urbanization, a growing middle class, and expansion of private eye hospitals are driving surgical volumes. In addition, improved insurance coverage and domestic manufacturing of affordable IOLs and surgical devices are strengthening local market development. The push for vision health awareness and access in rural areas continues to shape future growth.
Cataracts Market Share
The cataracts industry is primarily led by well-established companies, including:
- Alcon Management S. A. (Switzerland)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Merck & Co. Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Amorphex Therapeutics Holdings Inc. (U.S.)
- Astellas Pharma Inc. (Japan)
- Bayer AG (Germany)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Amgen Inc. (U.S.)
- Carl Zeiss AG (Germany)
- HumanOptics Holding AG (Germany)
- STAAR SURGICAL (U.S.)
What are the Recent Developments in Global Cataracts Market?
- In February 2024, Johnson & Johnson MedTech, a prominent leader in eye health, introduced the TECNIS PureSee presbyopia-correcting intraocular lens (IOL) across the EMEA region. Featuring a purely refractive design, the TECNIS PureSee IOL delivers seamless, high-quality vision with outstanding contrast sensitivity and low-light performance. It offers visual clarity comparable to monofocal lenses while addressing presbyopia, setting a new benchmark in advanced lens technology
- In September 2024, Alcon, a global leader in eye care committed to enhancing vision, unveiled new innovations at the European Society of Cataract and Refractive Surgeons (ESCRS) Annual Meeting in Barcelona. Among the highlights was the launch of the SMARTCataract DX digital planning solution—powered by the ARGOS Biometer and upcoming Alcon diagnostic tools—aimed at optimizing clinical workflows and improving procedural efficiency for ophthalmic practices
- In September 2024, Johnson & Johnson, a global leader in eye health, has announced the expanded U.S. rollout of its latest innovation in presbyopia-correcting intraocular lenses (PC-IOL), the TECNIS Odyssey. This next-generation full-range IOL provides patients with seamless, continuous vision across all distances—from far to near and everything in between significantly reducing dependence on glasses
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CATARACT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CATARACT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CATARACT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 PIPELINE ANALYSIS
13.1 CLINICAL TRIALS AND PHASE ANALYSIS
13.2 DRUG THERAPY PIPELINE
13.3 PHASE III CANDIDATES
13.4 PHASE II CANDIDATES
13.5 PHASE I CANDIDATES
13.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL ANALYSIS CATARACT MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR CATARACT MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR CATARACT MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR CATARACT MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR CATARACT MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
14 REIMBURSEMENT FRAMEWORK
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
17 GLOBAL CATARACT MARKET, BY TYPE
17.1 OVERVIEW
17.2 DIAGNOSIS
17.2.1 VISUAL ACUITY TEST
17.2.2 SLIT-LAMP EXAMINATION
17.2.3 RETINAL EXAM
17.2.4 TONOMETRY TEST
17.2.5 OTHERS
17.3 TREATMENT
17.3.1 NUCLEAR SCLEROTIC CATARACTS, BY TREATMENT PRODUCTS
17.3.1.1. INTRAOCULAR LENS (IOL)
17.3.1.1.1. MONOFOCAL IOL
17.3.1.1.1.1 HYDROPHILLIC MONOFOCAL LENS
17.3.1.1.1.2 HYDROPHOBIC MONOFOCAL LENS
17.3.1.1.2. TORIC IOL
17.3.1.1.3. MULTIFOCAL IOL
17.3.1.1.4. MONOVISION
17.3.1.1.5. OTHERS
17.3.1.2. OPHTHALMIC VISCOELASTIC DEVICE
17.3.1.2.1. COHESIVE OVD
17.3.1.2.2. DISPERSIVE OVD
17.3.1.3. FEMTOSECOND LASER EQUIPMENT, BY BRAND
17.3.1.3.1. INTRALASE
17.3.1.3.2. VISUMAX
17.3.1.3.3. FEMTO LDV
17.3.1.3.4. FEMTEC
17.3.1.3.5. OTHERS
17.3.1.4. OTHERS
17.3.2 CORTICAL CATARACTS, BY TREATMENT PRODUCTS
17.3.2.1. INTRAOCULAR LENS (IOL)
17.3.2.1.1. MONOFOCAL IOL
17.3.2.1.1.1 HYDROPHILLIC MONOFOCAL LENS
17.3.2.1.1.2 HYDROPHOBIC MONOFOCAL LENS
17.3.2.1.2. TORIC IOL
17.3.2.1.3. MULTIFOCAL IOL
17.3.2.1.4. MONOVISION
17.3.2.1.5. OTHERS
17.3.2.2. OPHTHALMIC VISCOELASTIC DEVICE
17.3.2.2.1. COHESIVE OVD
17.3.2.2.2. DISPERSIVE OVD
17.3.2.3. FEMTOSECOND LASER EQUIPMENT, BY BRAND
17.3.2.3.1. INTRALASE
17.3.2.3.2. VISUMAX
17.3.2.3.3. FEMTO LDV
17.3.2.3.4. FEMTEC
17.3.2.3.5. OTHERS
17.3.2.4. OTHERS
17.3.3 POSTERIOR SUBCAPSULAR CATARACTS, BY TREATMENT PRODUCTS
17.3.3.1. INTRAOCULAR LENS (IOL)
17.3.3.1.1. MONOFOCAL IOL
17.3.3.1.1.1 HYDROPHILLIC MONOFOCAL LENS
17.3.3.1.1.2 HYDROPHOBIC MONOFOCAL LENS
17.3.3.1.2. TORIC IOL
17.3.3.1.3. MULTIFOCAL IOL
17.3.3.1.4. MONOVISION
17.3.3.1.5. OTHERS
17.3.3.2. OPHTHALMIC VISCOELASTIC DEVICE
17.3.3.2.1. COHESIVE OVD
17.3.3.2.2. DISPERSIVE OVD
17.3.3.3. FEMTOSECOND LASER EQUIPMENT, BY BRAND
17.3.3.3.1. INTRALASE
17.3.3.3.2. VISUMAX
17.3.3.3.3. FEMTO LDV
17.3.3.3.4. FEMTEC
17.3.3.3.5. OTHERS
17.3.4 MEDICATIONS
17.3.4.1. MYDRIATICS
17.3.4.1.1. PHENYLEPHRINE OPHTHALMIC
17.3.4.1.2. TROPICAMIDE
17.3.4.1.3. OTHERS
17.3.4.2. NONSTEROIDAL ANTI-INFLAMMATORY OPHTHALMICS
17.3.4.2.1. NEPAFENAC OPHTHALMIC
17.3.4.2.2. BROMFENAC OPHTHALMIC
17.3.4.2.3. OTHERS
17.3.4.3. COMBINATION OPHTHALMICS
17.3.4.3.1. KETOROLAC/PHENYLEPHRINE OPHTHALMIC
17.3.4.3.2. OTHERS
17.3.4.4. CORTICOSTEROIDS
17.3.4.4.1. PREDNISOLONE ACETATE 1%
17.3.4.4.2. DEXAMETHASONE OPHTHALMIC
17.3.4.4.3. DIFLUPREDNATE OPHTHALMIC
17.3.4.4.4. LOTEPREDNOL OPHTHALMIC
17.3.4.4.5. OTHERS
17.3.4.5. ANTIBIOTICS
17.3.4.5.1. CIPROFLOXACIN OPHTHALMIC
17.3.4.5.2. MOXIFLOXACIN OPHTHALMIC
17.3.4.5.3. BESIFLOXACIN OPHTHALMIC
17.3.4.5.4. LEVOFLOXACIN OPHTHALMIC
17.3.4.5.5. ERYTHROMYCIN OPHTHALMIC
17.3.4.5.6. OTHERS
17.3.5 SURGERY
17.3.5.1. INCISION SURGERY
17.3.5.1.1. SMALL
17.3.5.1.2. LARGE
17.3.5.2. PHACOEMULSIFICATION
17.3.5.3. EXTRACAPSULAR CATARACT EXTRACTION
17.3.5.4. FEMTOSECOND LASER SURGERY
17.3.5.5. OTHERS
18 GLOBAL CATARACT MARKET, BY GENDER
18.1 OVERVIEW
18.2 MALE
18.2.1 PEDIATRIC
18.2.2 ADULT
18.2.3 GERIATRIC
18.3 FEMALE
18.3.1 PEDIATRIC
18.3.2 ADULT
18.3.3 GERIATRIC
19 GLOBAL CATARACT MARKET, BY END USER
19.1 OVERVIEW
19.2 HOSPITALS
19.2.1 BY TYPE
19.2.1.1. PRIVATE
19.2.1.2. PUBLIC
19.2.2 BY LEVEL
19.2.2.1. TIER 1
19.2.2.2. TIER 2
19.2.2.3. TIER 3
19.3 OPHTHALMIC CLINICS
19.4 AMBULATORY SURGICAL CENTERS
19.5 ACADEMIC AND RESEARCH INSTITUTES
19.6 OTHERS
20 GLOBAL CATARACT MARKET, BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 RETAIL SALES
20.3.1 ONLINE SALES
20.3.2 OFFLINE SALES
20.4 OTHERS
21 GLOBAL CATARACT MARKET, BY GEOGRAPHY
GLOBAL CATARACT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
21.1 NORTH AMERICA
21.1.1 U.S.
21.1.2 CANADA
21.1.3 MEXICO
21.2 EUROPE
21.2.1 GERMANY
21.2.2 FRANCE
21.2.3 U.K.
21.2.4 HUNGARY
21.2.5 LITHUANIA
21.2.6 AUSTRIA
21.2.7 IRELAND
21.2.8 NORWAY
21.2.9 POLAND
21.2.10 ITALY
21.2.11 SPAIN
21.2.12 RUSSIA
21.2.13 TURKEY
21.2.14 NETHERLANDS
21.2.15 SWITZERLAND
21.2.16 REST OF EUROPE
21.3 ASIA-PACIFIC
21.3.1 JAPAN
21.3.2 CHINA
21.3.3 SOUTH KOREA
21.3.4 INDIA
21.3.5 AUSTRALIA
21.3.6 SINGAPORE
21.3.7 THAILAND
21.3.8 MALAYSIA
21.3.9 INDONESIA
21.3.10 PHILIPPINES
21.3.11 VIETNAM
21.3.12 REST OF ASIA-PACIFIC
21.4 SOUTH AMERICA
21.4.1 BRAZIL
21.4.2 ARGENTINA
21.4.3 PERU
21.4.4 REST OF SOUTH AMERICA
21.5 MIDDLE EAST AND AFRICA
21.5.1 SOUTH AFRICA
21.5.2 GLOBAL
21.5.3 UAE
21.5.4 EGYPT
21.5.5 KUWAIT
21.5.6 ISRAEL
21.5.7 REST OF MIDDLE EAST AND AFRICA
21.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
22 GLOBAL CATARACT MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL CATARACT MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL CATARACT MARKET, COMPANY PROFILE
24.1 JOHNSON & JOHNSON, INC.
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 BAUSCH & LOMB INCORPORATED.
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 OCULENTIS MEDICAL PVT. LTD
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 NIDEK CO., LTD
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.5 CARL ZEISS MEDITECH AG
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 ABBOTT
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 ESSILOR
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 ALCON INC
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 STAAR SURGICAL
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 OMNI LENS PVT. LTD.
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 HOYA MEDICAL SINGAPORE PTE. LTD
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 LENSAR
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 AAREN LABS INC.
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 AKKOLENS CLINICAL BV
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 ALSANZA MEDIZINTECHNIK UND PHARMA GMBH.
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 1STQ DEUTSCHLAND GMBH
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 BVI
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
24.18 RAYNER GROUP
24.18.1 COMPANY OVERVIEW
24.18.2 REVENUE ANALYSIS
24.18.3 GEOGRAPHIC PRESENCE
24.18.4 PRODUCT PORTFOLIO
24.18.5 RECENT DEVELOPMENTS
24.19 HUMANOPTICS HOLDING AG
24.19.1 COMPANY OVERVIEW
24.19.2 REVENUE ANALYSIS
24.19.3 GEOGRAPHIC PRESENCE
24.19.4 PRODUCT PORTFOLIO
24.19.5 RECENT DEVELOPMENTS
24.2 TOPCON HEALTHCARE SOLUTIONS
24.20.1 COMPANY OVERVIEW
24.20.2 REVENUE ANALYSIS
24.20.3 GEOGRAPHIC PRESENCE
24.20.4 PRODUCT PORTFOLIO
24.20.5 RECENT DEVELOPMENTS
24.21 PRECISION LENS
24.21.1 COMPANY OVERVIEW
24.21.2 REVENUE ANALYSIS
24.21.3 GEOGRAPHIC PRESENCE
24.21.4 PRODUCT PORTFOLIO
24.21.5 RECENT DEVELOPMENTS
24.22 AUROLABS
24.22.1 COMPANY OVERVIEW
24.22.2 REVENUE ANALYSIS
24.22.3 GEOGRAPHIC PRESENCE
24.22.4 PRODUCT PORTFOLIO
24.22.5 RECENT DEVELOPMENTS
24.23 ZEIMER OPHTHALMIC SYSTEMS
24.23.1 COMPANY OVERVIEW
24.23.2 REVENUE ANALYSIS
24.23.3 GEOGRAPHIC PRESENCE
24.23.4 PRODUCT PORTFOLIO
24.23.5 RECENT DEVELOPMENTS
24.24 HANITA LENSES
24.24.1 COMPANY OVERVIEW
24.24.2 REVENUE ANALYSIS
24.24.3 GEOGRAPHIC PRESENCE
24.24.4 PRODUCT PORTFOLIO
24.24.5 RECENT DEVELOPMENTS
24.25 EYEKON MEDICAL INC
24.25.1 COMPANY OVERVIEW
24.25.2 REVENUE ANALYSIS
24.25.3 GEOGRAPHIC PRESENCE
24.25.4 PRODUCT PORTFOLIO
24.25.5 RECENT DEVELOPMENTS
24.26 APOLLO OPTICAL SYSTEMS
24.26.1 COMPANY OVERVIEW
24.26.2 REVENUE ANALYSIS
24.26.3 GEOGRAPHIC PRESENCE
24.26.4 PRODUCT PORTFOLIO
24.26.5 RECENT DEVELOPMENTS
24.27 RXSIGHT
24.27.1 COMPANY OVERVIEW
24.27.2 REVENUE ANALYSIS
24.27.3 GEOGRAPHIC PRESENCE
24.27.4 PRODUCT PORTFOLIO
24.27.5 RECENT DEVELOPMENTS
24.28 CARE GROUP
24.28.1 COMPANY OVERVIEW
24.28.2 REVENUE ANALYSIS
24.28.3 GEOGRAPHIC PRESENCE
24.28.4 PRODUCT PORTFOLIO
24.28.5 RECENT DEVELOPMENTS
24.29 HAAG STREIT HOLDING
24.29.1 COMPANY OVERVIEW
24.29.2 REVENUE ANALYSIS
24.29.3 GEOGRAPHIC PRESENCE
24.29.4 PRODUCT PORTFOLIO
24.29.5 RECENT DEVELOPMENTS
24.3 VALEANT PHARMACEUTICALS
24.30.1 COMPANY OVERVIEW
24.30.2 REVENUE ANALYSIS
24.30.3 GEOGRAPHIC PRESENCE
24.30.4 PRODUCT PORTFOLIO
24.30.5 RECENT DEVELOPMENTS
24.31 GLAUKOS CORPORATION
24.31.1 COMPANY OVERVIEW
24.31.2 REVENUE ANALYSIS
24.31.3 GEOGRAPHIC PRESENCE
24.31.4 PRODUCT PORTFOLIO
24.31.5 RECENT DEVELOPMENTS
24.32 ELLEX
24.32.1 COMPANY OVERVIEW
24.32.2 REVENUE ANALYSIS
24.32.3 GEOGRAPHIC PRESENCE
24.32.4 PRODUCT PORTFOLIO
24.32.5 RECENT DEVELOPMENTS
24.33 NOVARTIS AG
24.33.1 COMPANY OVERVIEW
24.33.2 REVENUE ANALYSIS
24.33.3 GEOGRAPHIC PRESENCE
24.33.4 PRODUCT PORTFOLIO
24.33.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
